Sound Dimension signs LOI with European IT services group to integrate AiFi for streamers
Bitget2026/10/06 13:10Sound Dimension signed a non-binding letter of intent with a European IT services and digital transformation group with more than 26,000 employees. The partner will act as sales channel and systems integrator for the AiFi audio-synchronization technology for international streaming customers. Commercial rollout starts immediately, initially targeting three selected streaming clients. Revenue-share model tied to license fees, plus income from joint customer projects. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sound Dimension AB published the original content used to generate this news brief via Cision (Ref. ID: 202610060909BITN____UKPR__SV_20261006-BIT-9773-0) on October 06, 2026, and is solely responsible for the information contained therein.
- Sound Dimension signed a non-binding letter of intent with a European IT services and digital transformation group with more than 26,000 employees.
- The partner will act as sales channel and systems integrator for the AiFi audio-synchronization technology for international streaming customers.
- Commercial rollout starts immediately, initially targeting three selected streaming clients.
- Revenue-share model tied to license fees, plus income from joint customer projects.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Former BioNTech executive leads Bambusa Therapeutics (BBTX.US) in sprint to Nasdaq, "boosting" eczema drug trials
Bambusa Therapeutics Inc. has filed for an initial public offering, planning to raise funds for clinical trials of treatments for eczema and other inflammatory diseases.
JPMorgan raises AbbVie target price to $300